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Background: Adolescent vaccination coverage varies considerably between Tdap, 
meningococcal, and HPV vaccines. While evidence suggests that health care access affects 
vaccination coverage, evidence does not explain whether access drives delayed or no 
vaccination. This study evaluates whether measures of health care access are associated with 
delayed vaccination or not being vaccinated by age 17 years for Tdap, meningococcal, and HPV 
vaccines when controlling for sociodemographic factors as proxies for vaccine hesitancy. The 
secondary objective assesses whether health care access measures had consistent associations 
across the different vaccines.  
Methods: Using current ACIP recommendations, ‘on-time’, ‘delayed’, and ‘missed’ status by 
age 17 were defined for Tdap, meningococcal, and HPV vaccinations. Vaccination coverage 
disparities among 17-year-olds by access and sociodemographic variables were assessed using 
data from NIS-Teen 2018. Associations between measures of health access and delayed or 
missed vaccination by age 17 were evaluated using multivariable logistic regression analysis. 
Results: For adolescents age 17 years, missing the 11–12 years well-child check-up was the 
strongest predictor for delayed or missed vaccination for Tdap, ≥1 dose MenACWY, and HPV. 
Other measures of health care access, such as continuity of insurance and number of health 
provider visits in the past 12 months, were not significantly associated with delayed or missed 
vaccination for any of the vaccines. 
Conclusions: For the small proportion of the adolescent population that does not have an 11–12-
year-old check-up, the detrimental effect on vaccination follows them through adolescence with 
a higher likelihood of no recommended vaccinations by age 17. The findings support a need to 
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The Advisory Committee on Immunization Practices (ACIP) recommends that children 
aged 13–17 years receive four vaccinations: a tetanus booster (Tdap); a meningococcal vaccine 
(MenACWY); the human papillomavirus (HPV) vaccine; and the seasonal influenza vaccine (1). 
Tdap is a decennial immunization, recommended at 11–12 years, primarily intended to provide 
tetanus prophylaxis in the case of wound exposure (2). Tdap is generally recommended over 
other tetanus toxoid containing vaccines to ensure continued protection against diphtheria and 
pertussis as well (2). MenACWY is given at 11–12 years (first dose) and 16–17 years (a second 
dose) to prevent meningococcal disease, which has a high case fatality rate and is easily 
transmitted in conjugate living facilities (e.g., college dorms or military barracks) (3,4). 
Vaccination against HPV in adolescence prevents sexually-transmitted infection and associated 
cervical, penile, vulvar, vaginal, anal, and oropharyngeal cancers and is given in a 2–3 dose 
schedule over 6–12 months depending on the child’s age at initiation (5).  
According to 2019 estimates, coverage with ≥1 dose of Tdap and ≥1 dose of the 
MenACWY remains high and stable among adolescents (1). The coverage for ≥1 dose of Tdap 
was estimated at 90.2%; for ≥1 dose of MenACWY, 88.9% (1). In contrast, only an estimated 
53.7% of adolescents received their age 16–17 MenACWY booster (1). Vaccination coverage of 
the meningococcal booster has increased steadily since 2014; however, the increase from 2018-
2019 was not statistically significant (1). While HPV coverage has increased steadily since it was 
first recommended by the ACIP in 2006, coverage remains lower than for other adolescent 
vaccines. Estimated coverage for ≥1 dose of HPV vaccine was 71.5% for all adolescents, with 
only 54.2% receiving enough doses to be considered up-to-date (UTD) for the multi-dose series 
(1,12). The fact that rates of ≥1 dose Tdap and ≥1 dose MenACWY coverage increased only 
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slightly over the last five years may indicate that coverage for those immunizations has reached a 
ceiling. Nonetheless, there is still much progress that can be made to achieve two doses of 
MenACWY by age 17 and higher rates of HPV vaccine initiation and completion. 
Evidence indicates that Tdap, MenACWY, and HPV vaccination is often delayed to after 
the recommended ages of 11–12 years. Previous research examining vaccination rates among 17-
year-old females in NIS-Teen-2013 indicated that large percentages of the cohort do not receive 
Tdap or at least one dose of MenACWY or HPV vaccine by age 13 (6). Tdap vaccination was 
delayed (i.e., received between ages 13–17 years) in 29% of the study population who reported 
receiving at least one dose (6). Forty percent of those who received at least one dose of 
MenACWY vaccine had their first dose after 11–12 years (6). HPV vaccination was the most 
frequently delayed vaccination: 47% of individuals 13–17-years-old who received at least one 
dose initiated the vaccine series after age 13 (6). NIS-Teen 2018 similarly shows that Tdap, 
MenACWY, and HPV vaccination is often delayed. 
 Existing literature demonstrates associations between measures of access to healthcare 
and adolescent vaccination completion. Previous research examining associations between health 
insurance status and vaccination coverage in NIS-Teen 2015 indicated that overall vaccination 
coverage for adolescents aged 13–17 years was lower for uninsured adolescents (7). The analysis 
also linked having an 11–12 well-child visit or at least two health care provider visits in the past 
year to an increased likelihood of receiving the recommended vaccinations (7). The study 
concluded that more contacts with health care providers meant more opportunities for providers 
to recommend and provide vaccinations. Those results were consistent with earlier data from 
NIS-Teen 2009, which found that adolescents who made at least one visit during which a vaccine 
was administered between ages 11–12 years were most likely to receive Td/Tdap on-time (8).  
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In order to evaluate the impact of health care access on timely vaccination, it is important 
to control for vaccine hesitancy, another important barrier to uptake. Sociodemographic 
characteristics can be markers of vaccine hesitancy. A study of the 2010 NIS-Teen dataset 
examined the association between sociodemographic characteristics and HPV initiation for 
adolescent females before and after age 13 years, and found differences among those who were 
vaccinated on-schedule, who delayed vaccination, or who refused (9). Girls in the group that 
delayed were more likely to be non-Hispanic white and be from more affluent sociodemographic 
households (9). Of the parents of girls who delayed vaccination, over 45% cited reasons related 
to vaccine effectiveness and safety (9). The sociodemographic characteristics of girls who 
refused HPV vaccination were more mixed, but those who delayed and then refused were more 
likely to be non-Hispanic white, come from the highest income households, and have older, 
highly-educated, married mothers (9). Additional evidence from an analysis of NIS-Teen 2011 
supports that white adolescents are more likely to cite hesitancy and lack of intent to initiate 
HPV vaccination compared to racial/ethnic minorities (10). The 2010 group that ultimately 
refused HPV vaccination also had the highest percentage of parents citing doubt about vaccine 
effectiveness, long-term safety, and need for HPV vaccination (9). The 2010 data showed that 
access was a barrier to on-schedule, HPV initiation, but was less significant for HPV completion:  
parents of girls who delayed, but ultimately completed, vaccination were more likely to state 
inconvenience as a reason for not meeting recommendations than parents who refused the HPV 
vaccine (9).  
These prior findings demonstrate that access to care is associated with vaccination 
coverage and that there are differences between adolescents who vaccinate on the recommended 
schedule or who delay. However, the access to care predictors of delayed vaccination have not 
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been fully examined (7,9). Also, while evidence supports delayed initiation of both Tdap and 
meningococcal vaccines as significant risk factors for delayed initiation of HPV vaccines in 
adolescent females, evidence is missing as to whether the same predictors drive delay of all three 
vaccines. This analysis addresses those limitations by identifying independent predictors of not 
being vaccinated on time at ages 11–12, and then assessing each significant predictor’s relation 
to health care access when adjusted for sociodemographic variables in a nationally representative 
sample of adolescents aged 17 years. Secondarily, the analysis examined the consistency of each 
predictor across Tdap, MenACWY, and HPV immunizations.  
Research Questions: Are health care access measures independently associated with delayed or 
no receipt of Tdap, MenACWY, and HPV vaccines, after controlling for sociodemographic 
factors as proxies for vaccine hesitancy? Is there consistency across different vaccines? 
Methods 
Part 1: Study Population/Data 
This study utilized data from the 2018 National Immunization Survey-Teen. The National 
Immunization Survey-Teen (NIS-Teen) is an annual survey conducted by the Centers for Disease 
Control and Prevention to obtain and assess data on immunization coverage for adolescents age 
13 to 17 years. The NIS-Teen survey is a representative stratified, national, probability sample 
conducted in two phases. The first phase is a cell-phone, random-digit-dial (RDD) household 
interview of parents/guardians of adolescents; 2018 was the first year the landline sample was 
excluded and the RDD sample design was limited to only cell-phones (11). The household 
interview includes questions on general health status, demographics, health insurance, vaccine 
history and any reasons for missed vaccinations. Parents/guardians also provide the names of the 
adolescent’s vaccination providers and oral consent to contact them. The response rate to the 
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household interview in 2018 was 71.9% (11). The second phase is an immunization history 
questionnaire mailed or faxed to each of the adolescent’s vaccination providers to confirm 
vaccination status and dates. The overall proportion of adolescents with returned provider 
surveys containing adequate immunization histories was 48.3% (11).  
In the 2018 survey, among the 18,700 adolescents with complete household interviews 
and adequate provider-reported vaccination histories, 3,480 (20%) of respondents were 17 years 
old at the time of the household interviews. Since the adolescent catch-up period includes 
immunization up to age 17, analysis was limited to only 17-year-olds to capture vaccine 
coverage when catch-up immunization should be complete. The final sample size was n=3,480. 
Part 2: Defining Variables 
 The outcomes of interest were: completion of the recommended doses for each vaccine 
by the recommended age (13 years for Tdap, HPV and the first MenACWY dose), defined as 
‘on-time’; completion by age 17 years, ‘delayed’; or no recorded doses by age 17 years, 
‘missed’. Since HPV vaccination requires a multiple dose schedule, it had an additional outcome 
for initiation by age 17. The second dose of MenACWY vaccine is recommended at age 16–17 
years, so the outcomes for MenACWY vaccine completion were 1 dose, ≥2 doses, or no doses 
by age 17 years. Adolescents who received their first MenACWY dose at 16–17 years were 
counted with those who only received their 11–12-year-old dose, since both lack one of the 
recommended doses.  Seasonal influenza vaccination is the fourth recommended adolescent 




 Table 1 summarizes what constitutes complete vaccination, the age to be considered on-
time, and the age for being classified as delayed. 
Table 1: Defining vaccination variables 






How is delayed 
completion 
defined for this 
vaccine? 
Tdap ≥1 dose 10–12 
(preferred 11–
12) 
≥1 dose by 17 
Meningococcal 
(≥1 dose) 
≥1 dose 11–12 ≥1 dose by 17 
HPV - Prior to Oct. 2016: 3 doses, 
regardless of age of initiation 
- Current: 2 doses if initiated 
before their 15th birthday. 3 
doses if initiated on or after 
their 15th birthday 




Recommended booster at age 16, 
which can be counted as: 1 dose 
at 16–17 or 2 doses by 17 
16–17 n/a within 
adolescence 
*An HPV initiation variable by age 17 was included for adolescents who had received ≥1 dose by 17, but who had not finished 
the sequence (12). 
†HPV catch-up can be completed as an adult by age 26 (12). 
 
Part 3: Selection of Correlates:  
 The following variables were used for measures of access to health care: continuity of 
insurance coverage since age 11; having had an 11–12-year-old well-child check-up; and the 
number of doctor or other health care professional visits reported in the last 12 months. Access to 
care variables were those that directly relate to a missed opportunity to vaccinate, i.e., missed 
preventive health visits.  
The following sociodemographic variables were used as proxies for measures of vaccine 
hesitancy: race/ethnicity of teen, sex of teen, poverty status, interview language, insurance status, 
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marital status of mother, educational level of mother, property rented/owned, number of children 
<18 years of age in the household, facility types for teen’s providers, and census region. 
Part 4: Statistical analysis 
The unadjusted association between health care access, sociodemographic characteristics 
of adolescents, and vaccine completion or initiation by 13 or 17 years includes unweighted 
sample numbers and weighted percentages. Weighted percentages by each of the characteristic 
covariates were calculated using RDD and provider weights described in the NIS-Teen 2018 
Data User’s Guide (11). The weighting variables reflect the probability of the adolescents being 
included in the NIS-Teen sample and additional poststratification weights to better represent the 
national demographic characteristics of all adolescents 13–17 years (11). Likelihood ratio chi-
square tests were used to find the unadjusted association between characteristic and on-time or 
delayed vaccine completion. 
 Multivariable logistic regression was conducted to assess the independent effects of each 
characteristic. The full, adjusted models included all characteristics to control for each covariate. 
To produce the reduced model of only significant predictors, backwards elimination was used to 
delete covariates that did not contribute to the regression based on the F statistic, with the 
significance level set at α<0.05. Adjusted odds ratios and 95% confidence intervals were 
reported for both the full and reduced models. An independent two-sided t test was used to assess 
associations, with the significance level set at α<0.05.  
Results 
In the 2018 National Immunization Survey-Teen, on-time (by 13 years of age) 
completion for HPV vaccination was only 15.3% among 17-year-olds (Table 2). Delayed 
completion of HPV vaccinations occurred at a much higher frequency than on-time vaccination: 
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41.0% of the cohort was up-to-date within the catch-up period (Table 2). An additional 12.8% of 
the sample initiated HPV vaccination, but did not complete all of their doses by age 17 (Table 2). 
HPV vaccination is the most frequently missed adolescent vaccination: 30.8% of 17-year-olds 
received no doses. By comparison, only 10.6% of 17-year-olds missed Tdap, and 14.1% missed 
MenACWY entirely (Table 2). On-time completion of Tdap and ≥1 dose of MenACWY vaccine 
was higher, 78.8% and 69.5%, respectively. However, this means that adolescents who delayed 
or missed vaccinations still made up 20% and 30%, respectively, of each group (Table 2). As 
shown in Table 3, approximately half (48.3%) of adolescents received ≥2 MenACWY doses by 
age 17.  
Among the health care access measures, the frequency of responses that indicate lower 
access varied considerably between the different measures. In the 17-year-old cohort, 390 teens 
(11.2%) reported gaps in insurance coverage since they were 11 years-old. For well-child visits, 
only 132 adolescents (3.8%), reported that they did not have an 11–12 years well-child visit, and 
an additional 259 (7.4%) didn’t know or didn’t report whether or not they had the well-child 
visit. For visits within the past year, while two-thirds (2,133) of 17-year-olds in the survey 
reported two or more health care provider visits, of the remaining respondents, 892 (25.6%) 
reported only one provider visit in the past year and 421 (12.1%) reported zero visits. 
Neither continuity of insurance nor number of health provider visits in the past 12 months 
were significant predictors of delayed vaccine uptake or no doses by age 17 years. In the 
unadjusted Chi-square associations, lack of continuity of insurance was significantly associated 
with a decrease in on-time completion for Tdap (p<0.001) and the first dose of MenACWY 
(p<0.001) (Tables 4 & 5). Continuous insurance was also significantly associated with an 
increase in overall completion of the MenACWY booster dose (p=0.044) (Table 6). At least one 
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provider visit in the past year was significantly associated with an increase in on-time Tdap 
completion (p=0.015) (Table 4). In addition, at least one provider visit in the past year was also 
significantly associated with receipt the 2nd MenACWY dose in the unadjusted analysis 
(p<0.001) (Table 6). Continuity of health insurance and health care provider visits in the past 12 
months were not associated with HPV vaccination (Table 7). 
Tables 8-15 show the full and reduced models for each vaccine for comparison. After 
controlling for sociodemographic characteristics as markers of vaccine hesitancy, the 11–12-
year-old well-visit exam was the only significantly associated access to care variable across all 
three vaccines in the full and reduced models (Tables 8-15). The odds of a teen without the 11–
12 years well-visit receiving their Tdap vaccine after the recommended age was 4.26 times the 
odds of a teen who had the check-up (Table 9). Teens with no 11–12 years check-up were also 
4.39 times more likely to receive no Tdap doses when compared to those who had their well-
child visit (Table 9). 
Teens who missed their 11–12 years check-up were 6.25 times more likely to receive 
their first MenACWY dose after the recommended age (Table 11). Missing the age 11–12 well-
child visit was also the strongest predictor for missing all meningococcal vaccinations: teens who 
missed the check-up were 10.75 times more likely to have no MenACWY doses by age 17 
(Table 11). The second dose of MenACWY was the only adolescent vaccine for which missing 
the 11–12-year-old well-child visit did not have a significant association when compared with 
adolescents who only received one dose (Table 13).  
The well-visit exam was also a strong predictor for HPV vaccination completion. When 
compared to adolescents who had the visit, those who did not were 4.86 times more likely to 
complete their doses during the catch-up period, rather than on-time (Table 15). No 11–12 years 
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check-up also increased odds of initiating the HPV vaccination schedule by age 17, but failing to 
complete it, to 11.69 times the odds of adolescents who reported having the check-up (Table 15). 
Teens who missed the 11–12-year-old well-visit were 15.70 times more likely to have received 
no HPV doses by age 17 (Table 15).   
Discussion 
Overall, the proportion of adolescents who completed their Tdap, meningococcal, and 
HPV vaccinations by the recommended age varied greatly between the different vaccines. 
Among those who did not receive Tdap (21.2%) or the 1st MenACWY dose (30.5%) on-time, 
about half of the remainder caught-up by 17 and the other half remained unvaccinated. However, 
the fact that only 15.3% of adolescents completed the HPV vaccination series on-time, and 
nearly 85% did not, indicates that a lot of progress still needs to be made in providing HPV 
vaccines within the recommended time frame. With such large differences in on-time and 
delayed uptake of the adolescent vaccinations, we were interested in which health care access 
measures were predictors for delayed or missed vaccination for each vaccine and whether those 
measures were consistent drivers across all adolescent vaccinations. 
Of the three health care access measures—continuity of insurance, number of provider 
visits in past year, and the 11–12-year-old well-child exam—only the well-child exam was 
significantly associated with delayed or missed vaccination for the three adolescent vaccinations. 
Unsurprisingly, the 11–12-year-old check-up was a highly consistent predictor for all 
vaccinations that are recommended to be given during those years. However, the proportion of 
17-year-olds who missed their 11–12-year-old check-up is only about 3.8% among those with 
provider data and 4.5% of all 17-year-olds in NIS-Teen 2018 sample. Since 11–12 years well-
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visit attendance is so high, clinicians should not miss the opportunity to vaccinate at this visit, 
but if they do, all subsequent visits should be viewed as opportunities for catch-up. 
Since so few adolescents miss the 11–12-year-old well-child exam, even if all 
adolescents had the check-up, the overall impact on vaccination coverage would likely be very 
small. If coverage with ≥1 dose Tdap and 1st dose MenACWY has reached a ceiling effect, a 
push for universal 11–12-year-old well-child exams would offer only a slight increase compared 
to current coverage. The number of adolescents who reported attending the 11–12-year-old well-
child visit has increased from 55% in 2009 to about 96% in 2018 (8). The large increase in well-
visit attendance may explain why other access to care measures were not strong predictors of 
delayed or missed vaccination in 2018. 
Among the sociodemographic measures that were proxies for hesitancy there were 
common predictors between the different vaccinations and common measures with no 
association. Adolescents living in the Midwest were significantly more likely to delay or not 
vaccinate for all three vaccinations compared to adolescents from the Northeast. In contrast, 
adolescents residing in the South and West were more likely to delay MenACWY and HPV 
vaccinations, but not Tdap. Adolescents whose household interviews were not conducted in 
English had an increased risk for delayed or missed vaccination for both Tdap and ≥1 dose of 
MenACWY. Household income and maternal education and marital status were not associated 
with on-time receipt of any of the vaccinations.  
Racial and ethnic minorities were more likely than non-Hispanic white adolescents to 
receive meningococcal and HPV vaccinations. This is in line with previous evidence suggesting 
that the parents of white adolescents are less likely to vaccinate and more likely to cite concerns 
related to vaccine hesitancy (10). Interestingly, being a racial or ethnic minority was not a strong 
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predictor of increased likelihood of on-time vaccination when comparing delayed receipt of ≥1 
dose of MenACWY to on-time vaccination, but it was or when comparing with those who 
received no doses. There was also a strong protective effect when comparing between those who 
received the 2nd MenACWY dose and those who only received one. Racial and ethnic 
associations with delayed or missed vaccination may imply that hesitancy has a greater effect 
with vaccinations that require doses to be given at multiple visits over time as opposed to one 
that can be completed in one visit, but there is not enough evidence to support this. Quadrivalent 
meningococcal and HPV vaccines were also licensed more recently (2005 and 2006), which may 
also contribute to increased hesitancy for both vaccines (5,12). 
Limitations 
 One limitation in designing the outcomes of the vaccination variables was in defining the 
parameters for the 1st and 2nd dose of MenACWY. The first of two adolescent doses of 
MenACWY should be given between 11–12 years with a catch-up period through age 15 years 
(5). The booster dose should be administered at ages 16–18 years (5). Therefore, a second dose 
given prior to age 16, does not fall within the recommended booster timeframe and could be 
counted as receiving only the first dose. Also, individuals who received their first dose at or after 
age 16 years would have fulfilled the requirement for the booster dose, but not for the initial 
recommended adolescent dose. In order to compare across all the adolescent vaccinations, in this 
study, any individual who received one dose, regardless of the age at immunization, was 
considered to have met the requirements for the 1st dose of MenACWY. Similarly, any 
individual who received at least two doses, regardless of the age at immunization, was 
considered to have fulfilled both recommended MenACWY doses. 
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This analysis is also limited by the fact that only adolescents with verified provider data 
were included in the NIS-Teen dataset. Lu et al. reason that sample bias in selecting NIS-Teen 
respondents with provider data may underestimate measures of health care access since 
uninsured teens may not have a consistent provider who has their full vaccination history and 
therefore, they may be excluded due to inadequate provider data (7). Some adjustments are made 
in calculating the sampling weights to account for provider nonresponse, but a bias in the 
estimates might remain (11). In looking at the proportion of adolescents who missed their 11–12-
year-old well-child exam, there is a difference between teens who had adequate provider data 
and teens who did not, but more work would need to be done to determine if there is a true 
difference and its magnitude. 
The number of provider visits in the past 12 months has limited meaning when 
considering on-time completion of vaccinations recommended at ages 11–12 years. Adolescence 
is a period marked by relatively few health visits, so it stands to reason that the number of 
provider visits might differ at age 16–17 years compared to 11–13 years (13). Also, current 
health care access for a 17-year-old is not necessarily indicative of what the adolescent’s health 
access looked like at age 12–13, so the number of visits in the past year might be more 
meaningful if analyzing vaccination coverage among 13-year-olds. 
This analysis was not able to account for all of the barriers that may be caused by lack of 
health care access and proxy measures for vaccine hesitancy were imperfect. For simplicity, 
measures of health care access were variables that had a direct relation to a missed opportunity to 
vaccinate—in other words, a missed preventive health visit. With respect to vaccine hesitancy, 
while all of the sociodemographic variables that were used as measures of hesitancy are 
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frequently correlated with increased hesitancy—and were therefore assigned as proxies—all also 
have implications that may indirectly affect an individual’s access to vaccination services.  
One instance in which the selected sociodemographic variables may not have fully 
captured vaccine hesitancy is with respect to missed HPV vaccination. An assumption could be 
made that higher rates of missed HPV vaccination (30.8%) as compared to Tdap (10.6%) or 
MenACWY (14.1%) were due to higher rates of vaccine refusal (Table 2). Explicit parental 
reasoning for HPV refusal due to concerns about sexual activity has decreased over time; 
however, concerns relating to vaccine safety and the need for HPV vaccination are much higher 
than for Tdap or MenACWY (14). The reasons why parents refuse HPV vaccination for their 
children are multi-faceted, but hesitancy is given as a primary reason more frequently among 
parents who ultimately refuse the vaccine for their children (9,14) 
Future Directions 
A longitudinal analysis of NIS-Teen datasets would indicate if health care access 
measures are consistent drivers over time as well as between the different vaccines.  Analyzing 
trends longitudinally could also provide insight into whether or not a ceiling has been reached in 
Tdap and 1st dose MenACWY vaccination. Consistent associations over time could reveal a 
characteristic of access or hesitancy that is a repeated barrier to adolescent vaccination coverage, 
which could be useful to know and account for in future vaccination campaigns.  
Future analysis could also be stratified by the adolescent’s residence in a Metropolitan 
Statistical Area (MSA) to examine regional variability. In this analysis, there was consistent 
association between census region and delayed or missed vaccination. However, since each 
census region is so large, the implications of census region being a predictor for delayed or 
missed vaccination is not particularly meaningful in terms of creating vaccination programs or 
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policies. Stratification by adolescents living in MSA/non-MSA areas, however, would provide 
more context on impact of health care access across the rural-urban divide. Previous research 
demonstrates that proximity to health care in rural areas has an effect on adolescent vaccination, 
so it would be interesting to see how the measures of access in this analysis compare across 
MSA status. 
Conclusions 
 Adolescents who miss the 11-12-year-old well-child visit are more likely to have delayed 
completion of all the adolescent vaccinations. Additionally, this group has the highest odds of 
missed vaccination at age 17 years. Among the small proportion of adolescents who miss the 11–
12-year-old well-child exam, there are lasting repercussions on the adolescent’s ability to catch-
up on their adolescent vaccination. More evidence is needed to know why this group is less 
likely to catch-up on vaccinations at subsequent well-child exams during adolescence. Additional 
analyses would need to be done to determine characteristics that correlate with missing the 11–
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Table 2: All NIS-Teen 2018 respondents age 17 years stratified by vaccination completion 
 Completed by age 
13 (on-time) 
Completed by 17 
(not by 13) 
Initiation – no 
completion 
No doses by 17 
Tdap 2743 (78.8) 369 (10.6) --- 368 (10.6) 
Meningococcal 2418 (69.5) 571 (16.4) --- 491 (14.1) 






Table 3:  Meningococcal 2nd dose completion by age 17, NIS-Teen 2018 
 1 dose only  2 doses  No doses 








Table 4: Characteristics of adolescents age 17 years stratified by on-time (by 13), delayed (by 17), or no 





complete by 13 
years 
n (%) 
complete by 17 
years 
n (%) no doses 
by 17 years 
p 
Race/ethnicity     0.087 
     Non-Hispanic white 2123 1723 (83.9) 191 (7.5) 209 (8.6)  
     Non-Hispanic black 290 227 (80.5) 34 (13.0) 29 (6.5)  
     Hispanic 692 522 (78.8) 85 (11.6) 85 (9.6)  
     Other + multiple race 375 271 (80.2) 59 (7.2) 45 (12.6)  
Poverty Status     <0.001 
     Above poverty 
(>$75K) 
1766 1449 (85.4) 145 (5.6) 172 (8.9)  
     Above poverty 
(<=$75K) 
1038 795 (79.9) 123 (11.5) 120 (8.6)  
     Below poverty 554 407 (73.3) 84 (16.1) 63 (10.5)  
Sex     0.461 
     Female 1589 1274 (83.4) 153 (8.5) 162 (8.2)  
     Male 1891 1469 (80.6) 216 (9.7) 206 (9.7)  
Interview Language     <0.001 
     English 3120 2500 (84.0) 301 (7.5) 319 (8.5)  
     Other 360 243 (66.5) 68 (20.9) 49 (12.6)  
Insurance status     <0.001 
     Private insurance only 2026 1659 (85.4) 170 (6.7) 197 (7.9)  
     Any Medicaid 1016 775 (79.6) 129 (11.4) 112 (9.0)  
     Other insurance** 287 215 (78.9) 35 (7.0) 37 (14.1)  
     Uninsured 151 94 (58.9) 35 (27.4) 22 (13.7)  
Maternal marital status     0.856 
     Married 2449 1943 (81.5) 252 (9.4) 254 (9.1)  
     Not married*** 1031 800 (82.6) 117 (8.6) 114 (8.8)  
Maternal education     0.001 
     College grad 1663 1366 (85.2) 143 (6.2) 154 (8.6)  
     More than 12 years, 
non-college grad 
906 714 (84.8) 99 (7.9) 93 (7.4)  
     12 years 521 377 (75.7) 74 (13.9) 70 (10.5)  
     Less than 12 years 390 286 (74.0) 53 (14.6) 51 (11.3)  
Property rented/owned     <0.001 
     Owned/being bought 2548 2090 (85.2) 218 (6.9) 240 (7.9)  
     Rented/other 921 645 (74.2) 148 (14.1) 128 (11.6)  
# of children <18     0.936 
     1 1699 1333 (82.5) 180 (8.4) 186 (9.1)  
     2–3 1492 1189 (81.3) 151 (9.7) 152 (9.0)  
     4+ 289 221 (82.0) 38 (9.8) 30 (8.2)  
Facility type     <0.001 
     All private 1492 1243 (86.1) 116 (6.2) 133 (7.7)  
     Public/hospital/ 
STD/school/teen clinics 
931 683 (72.3) 137 (15.1) 111 (12.6)  
     Mixed 620 508 (87.3) 67 (7.4) 45 (5.2)  
Census region     0.006 
     Northeast 681 600 (89.9) 43 (5.3) 38 (4.8)  
     Midwest 779 601 (75.9) 95 (12.0) 83 (12.1)  
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     South 1291 996 (80.1) 138 (10.6) 157 (9.3)  
     West 729 546 (84.9) 93 (6.7) 90 (8.3)  
Consistency of health 
insurance 
    <0.001 
     Current & no gaps 3079 2471 (83.6) 298 (7.9) 310 (8.5)  
     Intermittent/no 
insurance 
390  265 (68.7) 69 (18.7) 56 (12.6)  
11–12 well-child?     <0.001 
     Yes 3089 2508 (84.6) 281 (7.7) 300 (7.7)  
     No 132 67 (50.1) 34 (25.9) 31 (24.0)  
# of visits in last 12 
months 
       0.015 
     0 421 310 (72.5) 57 (15.5) 54 (12.0)  
     1 892 697 (82.0) 92 (9.1) 103 (8.9)  
     2+ 2133 1713 (83.8) 217 (7.9) 203 (8.3)  
* Numbers may not sum to total due to missing data 
** Other insurance: CHIP, IHS, Military, or other alone or in combination w/ private insurance 






Table 5 Characteristics of adolescents age 17 years stratified by on-time (by 13), delayed (by 17), or no 




n (%) ≥1 dose 
by 13 years 
n (%) ≥1 dose 
by 17 years 
n (%) no 
doses by 17 
years 
p 
Race/ethnicity     0.046 
     Non-Hispanic white 2123 1470 (72.2) 332 (14.4) 321 (13.4)  
     Non-Hispanic black 290 213 (77.5) 41 (14.0) 36 (8.5)  
     Hispanic 692 498 (73.6) 124 (19.4) 70 (7.0)  
     Other + multiple race 375 237 (70.4) 74 (16.0) 64 (13.6)  
Poverty Status     0.017 
     Above poverty (>$75K) 1766 1279 (76.3) 244 (12.6) 243 (11.2)  
     Above poverty 
(<=$75K) 
1038 677 (71.3) 189 (17.1) 172 (11.6)  
     Below poverty 554 381 (65.9) 109 (21.7) 64 (12.3)  
Sex     0.128 
     Female 1589 1128 (75.1) 260 (15.3) 201 (9.5)  
     Male 1891 1290 (71.2) 311 (15.9) 290 (12.9)  
Interview Language     <0.001 
     English 3120 2179 (74.3) 481 (13.9) 460 (11.9)  
     Other 360 239 (63.9) 90 (28.4) 31 (7.7)  
Insurance status     <0.001 
     Private insurance only 2026 1454 (76.6) 300 (13.5) 272 (9.9)  
     Any Medicaid 1016 697 (70.7) 178 (17.7) 141 (11.6)  
     Other insurance** 287 187 (68.1) 53 (12.0) 47 (19.8)  
     Uninsured 151 80 (52.6) 40 (33.7) 31 (13.8)  
Maternal marital status     0.884 
     Married 2449 1706 (73.2) 399 (15.0) 344 (11.7)  
     Not married*** 1031 712 (72.6) 172 (16.7) 147 (10.6)  
Maternal education     0.159 
     College grad 1663 1208 (76.2) 249 (13.8) 206 (10.0)  
     More than 12 years, 
non-college grad 
906 604 (73.6) 149 (14.9) 153 (11.5)  
     12 years 521 340 (70.0) 101 (17.1) 80 (12.9)  
     Less than 12 years 390 266 (65.1) 72 (21.5) 52 (13.4)  
Property rented/owned     <0.001 
     Owned/being bought 2548 1832 (76.1) 365 (13.1) 351 (10.8)  
     Rented/other 921 578 (65.9) 203 (21.3) 140 (12.8)  
# of children <18     0.100 
     1 1699 1170 (72.6) 262 (13.7) 267 (13.7)  
     2–3 1492 1057 (73.3) 252 (17.3) 183 (9.4)  
     4+ 289 191 (73.5) 57 (15.4) 41 (11.1)  
Facility type     <0.001 
     All private 1492 1149 (78.0) 202 (14.2) 141 (7.8)  
     Public/hospital/ 
STD/school/teen clinics 
931 568 (62.8) 199 (21.0) 164 (16.1)  
     Mixed 620 440 (75.6) 99 (12.6) 81 (11.7)  
Census region     <0.001 
     Northeast 681 569 (83.7) 80 (11.5) 32 (4.7)  
     Midwest 779 507 (66.8) 156 (19.7) 116 (13.5)  
     South 1291 900 (68.5) 200 (18.5) 191 (13.1)  
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     West 729 442 (78.9) 135 (9.9) 152 (11.2)  
Consistency of health 
insurance 
    <0.001 
     Current w/ no gaps 3079 2188 (74.7) 476 (14.2) 415 (11.1)  
     Intermittent/not insured 390 224 (60.4) 91 (26.3) 75 (13.4)  
11–12 well-child?     <0.001 
     Yes 3089 2245 (76.6) 470 (14.3) 374 (9.1)  
     No 132 41 (23.7) 43 (36.1) 48 (40.2)  
# of visits in last 12 
months 
    0.643 
     0 421 273 (68.1) 70 (17.7) 78 (14.3)  
     1 892 608 (73.8) 148 (15.5) 136 (10.7)  
     2+ 2133 1512 (73.5) 348 (15.4) 273 (11.1)  
* Numbers may not sum to total due to missing data 
** Other insurance: CHIP, IHS, Military, or other alone or in combination w/ private insurance 






Table 6: Characteristics of adolescents age 17 years stratified by receipt of 1st, 2nd or no doses: 




n (%) 1 dose 
by 17 years 
n (%) 2+ 
doses by 17 
years 
n (%) no 
doses by 17 
years 
p 
Race/ethnicity     0.037 
     Non-Hispanic white 2123 809 (36.9) 993 (49.7) 321 (13.4)  
     Non-Hispanic black 290 103 (30.5) 151 (61.0) 36 (8.5)  
     Hispanic 692 268 (39.0) 354 (54.0) 70 (7.0)  
     Other + multiple race 375 128 (39.1) 183 (47.3) 64 (13.6)  
Poverty Status     0.911 
     Above poverty (>$75K) 1766 638 (36.1) 885 (52.8) 243 (11.2)  
     Above poverty 
(<=$75K) 
1038 409 (35.5) 457 (52.9) 172 (11.6)  
     Below poverty 554 205 (38.6) 285 (49.1) 64 (12.3)  
Sex     0.035 
     Female 1589 589 (34.9) 799 (55.6) 201 (9.5)  
     Male 1891 719 (38.3) 882 (48.8) 290 (12.9)  
Interview Language     0.302 
     English 3120 1174 (36.5) 1486 (51.6) 460 (11.9)  
     Other 360 134 (37.8) 195 (54.5) 31 (7.7)  
Insurance status     0.004 
     Private insurance only 2026 736 (35.9) 1018 (54.2) 272 (9.9)  
     Any Medicaid 1016 376 (35.2) 499 (53.3) 141 (11.6)  
     Other insurance** 287 125 (39.6) 115 (40.6) 47 (19.8)  
     Uninsured 151 71 (52.1) 49 (34.1) 31 (13.8)  
Maternal marital status     0.303 
     Married 2449 916 (35.1) 1189 (53.1) 344 (11.7)  
     Not married*** 1031 392 (39.7) 492 (49.7) 147 (10.6)  
Maternal education     0.337 
     College grad 1663 573 (34.5) 884 (55.4) 206 (10.0)  
     More than 12 years, 
non-college grad 
906 374 (40.7) 379 (47.9) 153 (11.5)  
     12 years 521 217 (35.3) 224 (51.8) 80 (12.9)  
     Less than 12 years 390 144 (39.0) 194 (47.6) 52 (13.4)  
Property rented/owned     0.291 
     Owned/being bought 2548 930 (35.8) 1267 (53.4) 351 (10.8)  
     Rented/other 921 373 (38.7) 408 (48.5) 140 (12.8)  
# of children <18     0.114 
     1 1699 623 (37.9) 809 (48.4) 267 (13.7)  
     2–3 1492 570 (35.3) 739 (55.3) 183 (9.4)  
     4+ 289 115 (38.3) 133 (50.6) 41 (11.1)  
Facility type     0.003 
     All private 1492 540 (36.9) 811 (55.3) 141 (7.8)  
     Public/hospital/ 
STD/school/teen clinics 
931 373 (38.7) 394 (45.2) 164 (16.1)  
     Mixed 620 236 (36.4) 303 (51.9) 81 (11.7)  
Census region     <0.001 
     Northeast 681 170 (21.9) 479 (73.3) 32 (4.7)  
     Midwest 779 289 (37.6) 374 (48.9) 116 (13.5)  
     South 1291 533 (43.7) 567 (43.2) 191 (13.1)  
24 
 
     West 729 316 (34.8) 261 (54.1) 152 (11.2)  
Consistency of health 
insurance 
    0.044 
     Current w/ no gaps 3079 1127 (35.6) 1537 (53.3) 415 (11.1)  
     Intermittent/not insured 390 174 (43.8) 141 (42.8) 75 (13.4)  
11–12 well-child?     <0.001 
     Yes 3089 1161 (37.0) 1554 (54.0) 374 (9.1)  
     No 132 46 (34.1) 38 (25.7) 48 (40.2)  
# of visits in last 12 
months 
    <0.001 
     0 421 216 (53.2) 127 (32.5) 78 (14.3)  
     1 892 344 (36.2) 412 (53.1) 136 (10.7)  
     2+ 2133 739 (33.8) 1121 (55.1) 273 (11.1)  
* Numbers may not sum to total due to missing data 
** Other insurance: CHIP, IHS, Military, or other alone or in combination w/ private insurance 






Table 7: Characteristics of adolescents age 17 years stratified by up-to-date (UTD) by 13 years, UTD by 






age 13 years 
n (%) 
complete by 
age 17 years 
n (%) 
initiated by 
age 17 years 
n (%) no 
doses by age 
17 years 
p 
Race/ethnicity      <0.001 
     Non-Hispanic 
white 
2123 280 (12.6) 839 (38.7) 268 (11.8) 736 (36.9)  
     Non-Hispanic 
black 
290 46 (18.4) 142 (53.7) 39 (11.9) 63 (15.9)  
     Hispanic 692 152 (22.8) 279 (44.4) 89 (11.7) 172 (21.1)  
     Other + multiple 
race 
375 56 (11.3) 166 (47.2) 51 (9.8) 102 (31.7)  
Poverty Status      0.132 
     Above poverty 
(>$75K) 
1766 244 (12.8) 747 (41.7) 221 (11.8) 554 (33.7)  
     Above poverty 
(<=$75K) 
1038 155 (18.4) 399 (43.7) 128 (10.7) 356 (27.2)  
     Below poverty 554 116 (17.9) 226 (43.3) 81 (12.2) 131 (26.6)  
Sex      <0.001 
     Female 1589 326 (21.6) 674 (45.2) 205 (9.4) 384 (23.7)  
     Male 1891 208 (10.1) 752 (41.2) 242 (13.5) 689 (35.3)  
Interview Language      <0.001 
     English 3120 434 (14.0) 1278 (42.7) 399 (11.7) 1009 (31.6)  
     Other 360 100 (26.0) 148 (46.0) 48 (10.8) 64 (17.1)  
Insurance status      0.002 
     Private insurance 
only 
2026 276 (12.8) 861 (45.2) 243 (10.7) 646 (31.3)  
     Any Medicaid 1016 199 (21.2) 410 (41.3) 130 (12.4) 277 (25.1)  
     Other insurance** 287 38 (15.9) 101 (33.6) 43 (10.8) 105 (39.7)  
     Uninsured 151 21 (8.7) 54 (44.0) 31 (18.0) 45 (29.2)  
Maternal marital 
status 
     0.007 
     Married 2449 344 (14.4) 1000 (41.8) 299 (10.6) 806 (33.2)  
     Not married*** 1031 190 (17.5) 426 (45.5) 148 (13.5) 267 (23.5)  
Maternal education      0.224 
     College grad 1663 231 (13.2) 753 (45.6) 193 (10.1) 486 (31.0)  
     More than 12 
years, non-college 
grad 
906 120 (15.1) 339 (40.4) 125 (14.3) 322 (30.2)  
     12 years 521 83 (17.6) 187 (40.3) 75 (10.9) 176 (31.2)  
     Less than 12 years 390 100 (21.0) 147 (44.4) 54 (12.6) 89 (22.0)  
Property 
rented/owned 
     0.486 
     Owned/being 
bought 
2548 377 (15.7) 1050 (42.1) 307 (11.1) 814 (31.2)  
     Rented/other 921 154 (14.7) 373 (45.4) 137 (12.7) 257 (27.2)  
# of children <18      0.010 
     1 1699 261 (16.3) 679 (39.1) 227 (14.5) 532 (30.0)  
     2–3 1492 229 (15.1) 637 (47.7) 186 (9.5) 440 (27.7)  
     4+ 289 44 (13.6) 110 (37.3) 34 (9.4) 101 (39.8)  
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Facility type      0.459 
     All private 1492 239 (15.0) 661 (45.0) 189 (11.3) 403 (28.7)  
     Public/hospital/ 
STD/school/teen 
clinics 
931 146 (17.5) 335 (38.1) 132 (11.5) 318 (32.9)  
     Mixed 620 96 (15.7) 267 (47.5) 85 (11.0) 172 (25.7)  
Census region      0.169 
     Northeast 681 105 (14.1) 371 (52.7) 67 (7.2) 138 (26.0)  
     Midwest 779 117 (13.5) 305 (40.5) 99 (12.2) 258 (33.8)  
     South 1291 210 (16.2) 479 (41.5) 174 (41.5) 428 (30.7)  
     West 729 102 (17.1) 271 (41.1) 107 (14.2) 249 (27.6)  
Consistency of health 
insurance 
     0.303 
     Current & no gaps 3079 484 (16.1) 1279 (42.9) 379 (11.3) 937 (29.7)  
     Intermittent/not 
insured 
390 49 (10.7) 144 (45.5) 68 (13.9) 129 (30.0)  
11–12 well-child?      <0.001 
     Yes 3089 504 (16.7) 1308 (44.5) 377 (11.3) 900 (27.6)  
     No 132 5 (2.6) 35 (29.8) 31 (16.0) 61 (51.6)  
# of visits in last 12 
months 
     0.744 
     0 421 56 (18.1) 138 (37.5) 53 (11.4) 174 (32.9)  
     1 892 113 (13.7) 361 (43.7) 119 (12.9) 299 (29.7)  
     2+ 2133 354 (15.4) 919 (44.0) 269 (11.0) 591 (29.5)  
* Numbers may not sum to total due to missing data 
** Other insurance: CHIP, IHS, Military, or other alone or in combination w/ private insurance 














(95% CI) – no 
doses 
p – no 
doses 
Race/ethnicity     
     Non-Hispanic white 1.00 --- 1.00 --- 
     Non-Hispanic black 0.90 (0.43, 1.88) 0.782 0.64 (0.31, 1.32) 0.227 
     Hispanic 0.50 (0.22, 1.15) 0.102 1.07 (0.62, 1.85) 0.805 
     Other + multiple race 0.93 (0.50, 1.73) 0.816 2.13 (1.11, 4.10) 0.024 
Poverty Status     
     Above poverty (>$75K) 1.00 --- 1.00 --- 
     Above poverty (<=$75K) 1.54 (0.86, 2.78) 0.150 0.81 (0.49, 1.34) 0.409 
     Below poverty 1.46 (0.60, 3.59) 0.405 0.66 (0.31, 1.40) 0.279 
Sex     
     Female 1.00 --- 1.00 --- 
     Male 1.17 (0.76, 1.81) 0.465 1.10 (0.74, 1.65) 0.639 
Interview Language     
     English 1.00 --- 1.00 --- 
     Other 4.89 (1.85, 12.94) 0.001 1.78 (0.77, 4.18) 0.174 
Insurance status     
     Private insurance only 1.00 --- 1.00 --- 
     Any Medicaid 0.50 (0.23, 1.08) 0.077 1.30 (0.72, 2.36) 0.381 
     Other insurance** 0.53 (0.18, 1.63) 0.270 2.45 (1.20, 5.03) 0.014 
     Uninsured 0.80 (0.25, 2.63) 0.716 1.18 (0.31, 4.56) 0.811 
Maternal marital status     
     Married 1.00 --- 1.00 --- 
     Not married*** 0.64 (0.38, 1.06) 0.082 0.97 (0.56, 1.71) 0.928 
Maternal education     
     College grad 1.00 --- 1.00 --- 
     More than 12 years, non-
college grad 
1.54 (0.87, 2.74) 0.137 0.93 (0.55, 1.58) 0.794 
     12 years 1.74 (0.94, 3.22) 0.077 1.02 (0.56, 1.85) 0.948 
     Less than 12 years 1.34 (0.60, 3.01) 0.479 0.80 (0.31, 2.06) 0.637 
Property rented/owned     
     Owned/being bought 1.00 --- 1.00 --- 
     Rented/other 2.28 (1.35, 3.84) 0.002 1.35 (0.78, 2.33) 0.282 
# of children <18     
     1 1.00 --- 1.00 --- 
     2–3 1.01 (0.66, 1.54) 0.979 1.10 (0.70, 1.70) 0.688 
     4+ 1.09 (0.45, 2.65) 0.845 0.82 (0.35, 1.91) 0.639 
Facility type     
     All private 1.00 --- 1.00 --- 
     Public/hospital/ 
STD/school/teen clinics 
2.23 (1.38, 3.60) 0.001 1.51 (0.93, 2.45) 0.094 
     Mixed 0.87 (0.49, 1.53) 0.626 0.63 (0.35, 1.14) 0.126 
Census region     
     Northeast 1.00 --- 1.00 --- 
     Midwest 2.12 (1.09, 4.10) 0.027 2.48 (1.16, 5.30) 0.019 
     South 1.61 (0.84, 3.09) 0.151 1.88 (0.92, 3.84) 0.083 
     West 0.63 (0.30, 1.32) 0.218 1.67 (0.76, 3.66) 0.198 
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Consistency of health insurance     
     Current & no gaps 1.00 --- 1.00 --- 
     Intermittent/never insured 1.37 (0.59, 3.15) 0.465 1.71 (0.81, 3.62) 0.158 
11–12 well-child?     
     Yes 1.00 --- 1.00 --- 
     No 4.35 (2.07, 9.16) <0.001 3.68 (1.52, 8.90) 0.004 
# of visits in last 12 months     
     1 1.00 --- 1.00 --- 
     0 0.74 (0.33, 1.65) 0.465 0.68 (0.33, 1.41) 0.302 
     2+ 0.77 (0.47, 1.25) 0.288 0.68 (0.43, 1.08) 0.101 
** Other insurance: CHIP, IHS, Military, or other alone or in combination w/ private insurance 






Table 9: Multivariate logistic regression between study characteristics and Tdap vaccination (Reduced 
model), NIS-Teen 2018 
Characteristic 
Adjusted OR 




(95% CI) – no 
doses 
p – no 
doses 
Interview Language     
     English 1.00 --- 1.00 --- 
     Other 3.11 (1.70, 5.68) <0.001 1.88 (1.03, 3.45) 0.041 
Property rented/owned     
     Owned/being bought 1.00 --- 1.00 --- 
     Rented/other 1.98 (1.26, 3.12) 0.003 1.33 (0.86, 2.07) 0.205 
Facility type     
     All private 1.00 --- 1.00 --- 
     Public/hospital/ 
STD/school/teen clinics 
1.99 (1.22, 3.26) 0.006 1.45 (0.92, 2.30) 0.113 
     Mixed 0.91 (0.52, 1.59) 0.730 0.63 (0.35, 1.12) 0.116 
Census region     
     Northeast 1.00 --- 1.00 --- 
     Midwest 2.57 (1.32, 5.00) 0.006 2.60 (1.13, 6.00) 0.025 
     South 1.90 (1.00, 3.58) 0.049 1.97 (0.92, 4.23) 0.083 
     West 0.68 (0.33, 1.39) 0.287 1.74 (0.76, 3.97) 0.189 
11–12 well-child?     
     Yes 1.00 --- 1.00 --- 






Table 10: Multivariate logistic regression between study characteristics and ≥1 dose MenACWY (Full 
model), NIS-Teen 2018 
Characteristic 
Adjusted OR 




(95% CI) – no 
doses 
p – no 
doses 
Race/ethnicity     
     Non-Hispanic white 1.00 --- 1.00 --- 
     Non-Hispanic black 0.55 (0.28, 1.09) 0.087 0.30 (0.14, 0.62) 0.001 
     Hispanic 0.61 (0.30, 1.23) 0.167 0.41 (0.22, 0.73) 0.003 
     Other + multiple race 1.06 (0.56, 1.99) 0.869 0.74 (0.40, 1.35) 0.323 
Poverty Status     
     Above poverty (>$75K) 1.00 --- 1.00 --- 
     Above poverty (<=$75K) 1.40 (0.86, 2.27) 0.179 1.05 (0.61, 1.82) 0.857 
     Below poverty 1.03 (0.49, 2.19) 0.933 0.76 (0.29, 1.98) 0.571 
Sex     
     Female 1.00 --- 1.00 --- 
     Male 1.11 (0.77, 1.61) 0.571 1.17 (0.79, 1.71) 0.432 
Interview Language     
     English 1.00 --- 1.00 --- 
     Other 3.22 (1.48, 7.01) 0.003 0.76 (0.30, 1.71) 0.572 
Insurance status     
     Private insurance only 1.00 --- 1.00 --- 
     Any Medicaid 0.77 (0.42, 1.42) 0.401 1.46 (0.84, 2.55) 0.182 
     Other insurance** 0.46 (0.21, 0.99) 0.048 2.69 (1.40, 5.16) 0.003 
     Uninsured 1.00 (0.33, 3.01) 0.998 2.30 (0.74, 7.14) 0.149 
Maternal marital status     
     Married 1.00 --- 1.00 --- 
     Not married*** 1.04 (0.68, 1.60) 0.853 1.01 (0.62, 1.64) 0.979 
Maternal education     
     College grad 1.00 --- 1.00 --- 
     More than 12 years, non-
college grad 
1.26 (0.79, 2.03) 0.333 1.02 (0.61, 1.71) 0.943 
     12 years 1.14 (0.66, 1.97) 0.640 1.02 (0.53, 1.96) 0.950 
     Less than 12 years 0.72 (0.30, 1.74) 0.467 1.71 (0.72, 4.10) 0.227 
Property rented/owned     
     Owned/being bought 1.00 --- 1.00 --- 
     Rented/other 1.75 (1.06, 2.90) 0.086 1.40 (0.82, 2.39) 0.223 
# of children <18     
     1 1.00 --- 1.00 --- 
     2–3 1.52 (1.03, 2.24) 0.036 0.70 (0.46, 1.05) 0.086 
     4+ 1.23 (0.65, 2.32) 0.526 0.75 (0.35, 1.60) 0.455 
Facility type     
     All private 1.00 --- 1.00 --- 
     Public/hospital/ 
STD/school/teen clinics 
1.58 (1.06, 2.35) 0.024 2.23 (1.39, 3.57) 0.001 
     Mixed 0.96 (0.60, 1.56) 0.878 1.63 (0.96, 2.77) 0.071 
Census region     
     Northeast 1.00 --- 1.00 --- 
     Midwest 2.26 (1.25, 4.08) 0.007 5.27 (1.88, 14.77) 0.002 
     South 2.36 (1.33, 4.20) 0.004 7.01 (2.60, 18.92) <0.001 
     West 0.81 (0.42, 1.54) 0.512 5.63 (1.97, 16.10) 0.001 
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Consistency of health 
insurance 
    
     Current & no gaps 1.00 --- 1.00 --- 
     Intermittent/never insured 1.56 (0.78, 3.14) 0.211 1.08 (0.50, 2.37) 0.842 
11–12 well-child?     
     Yes 1.00 --- 1.00 --- 
     No 5.58 (2.64, 11.77) <0.001 7.46 (3.20, 17.43) <0.001 
# of visits in last 12 months     
     1 1.00 --- 1.00 --- 
     0 0.64 (0.33, 1.23) 0.180 1.01 (0.54, 1.88) 0.980 






Table 11: Multivariate logistic regression between study characteristics and ≥1 dose MenACWY 
(Reduced model), NIS-Teen 2018 
Characteristic 
Adjusted OR 




(95% CI) – no 
doses 
p – no 
doses 
Race/ethnicity     
     Non-Hispanic white 1.00 --- 1.00 --- 
     Non-Hispanic black 0.73 (0.39, 1.36) 0.320 0.38 (0.19, 0.76) 0.007 
     Hispanic 0.64 (0.30, 1.35) 0.239 0.45 (0.25, 0.80) 0.007 
     Other + multiple race 1.04 (0.59, 1.84) 0.897 0.99 (0.51, 1.90) 0.965 
Interview Language     
     English 1.00 --- 1.00 --- 
     Other 2.58 (1.19, 5.59) 0.016 0.61 (0.26, 1.42) 0.249 
Insurance status     
     Private insurance only 1.00 --- 1.00 --- 
     Any Medicaid 1.10 (0.68, 1.79) 0.702 1.52 (0.92, 2.51) 0.102 
     Other insurance** 0.67 (0.36, 1.25) 0.204 2.59 (1.36, 4.91) 0.004 
     Uninsured 1.92 (0.83, 4.43) 0.125 2.64 (1.11, 6.28) 0.029 
Facility type     
     All private 1.00 --- 1.00 --- 
     Public/hospital/ 
STD/school/teen clinics 
1.53 (1.04, 2.24) 0.030 2.12 (1.36, 3.32) 0.001 
     Mixed 0.92 (0.56, 1.51) 0.747 1.36 (0.81, 2.28) 0.246 
Census region     
     Northeast 1.00 --- 1.00 --- 
     Midwest 2.39 (1.35, 4.23) 0.003 3.53 (1.49, 8.37) 0.004 
     South 2.39 (1.36, 4.20) 0.002 4.71 (2.01, 11.00) <0.001 
     West 0.83 (0.45, 1.53) 0.548 3.41 (1.36, 8.53) 0.009 
11–12 well-child?     
     Yes 1.00 --- 1.00 --- 






Table 12: Multivariate logistic regression between study characteristics and 2+ dose MenACWY (Full 
model), NIS-Teen 2018 
Characteristic 
Adjusted OR 
(95% CI) – 1 dose 
only 
p – 1 
dose only 
Adjusted OR 
(95% CI) – no 
doses 
p – no 
doses 
Race/ethnicity     
     Non-Hispanic white 1.00 --- 1.00 --- 
     Non-Hispanic black 0.54 (0.32, 0.90) 0.018 0.25 (0.11, 0.54) 0.001 
     Hispanic 0.85 (0.52, 1.40) 0.527 0.42 (0.22, 0.79) 0.008 
     Other + multiple race 1.51 (0.87, 2.63) 0.147 0.89 (0.47, 1.68) 0.711 
Poverty Status     
     Above poverty (>$75K) 1.00 --- 1.00 --- 
     Above poverty (<=$75K) 0.84 (0.56, 1.26) 0.401 0.91 (0.52, 1.61) 0.755 
     Below poverty 0.81 (0.45, 1.46) 0.477 0.68 (0.25, 1.84) 0.452 
Sex     
     Female 1.00 --- 1.00 --- 
     Male 1.31 (0.96, 1.78) 0.085 1.32 (0.87, 1.99) 0.187 
Interview Language     
     English 1.00 --- 1.00 --- 
     Other 0.63 (0.30, 1.31) 0.215 0.41 (0.15, 1.14) 0.087 
Insurance status     
     Private insurance only 1.00 --- 1.00 --- 
     Any Medicaid 1.04 (0.62, 1.74) 0.885 1.58 (0.88, 2.83) 0.125 
     Other insurance** 1.33 (0.78, 2.24) 0.294 3.56 (1.80, 7.04) <0.001 
     Uninsured 1.85 (0.67, 5.10) 0.237 3.01 (0.78, 10.94) 0.094 
Maternal marital status     
     Married 1.00 --- 1.00 --- 
     Not married*** 1.15 (0.80, 1.65) 0.468 1.07 (0.64, 1.78) 0.809 
Maternal education     
     College grad 1.00 --- 1.00 --- 
     More than 12 years, non-
college grad 
1.62 (1.14, 2.30) 0.007 1.23 (0.72, 2.11) 0.444 
     12 years 1.30 (0.81, 2.09) 0.274 1.14 (0.58, 2.26) 0.708 
     Less than 12 years 1.55 (0.78, 3.09) 0.211 2.30 (0.91, 5.78) 0.078 
Property rented/owned     
     Owned/being bought 1.00 --- 1.00 --- 
     Rented/other 1.27 (0.83, 1.92) 0.269 1.40 (0.80, 2.45) 0.244 
# of children <18     
     1 1.00 --- 1.00 --- 
     2–3 0.82 (0.59, 1.13) 0.216 0.58 (0.37, 0.90) 0.015 
     4+ 1.04 (0.59, 1.83) 0.905 0.74 (0.34, 1.60) 0.440 
Facility type     
     All private 1.00 --- 1.00 --- 
     Public/hospital/ 
STD/school/teen clinics 
1.05 (0.74, 1.47) 0.800 2.06 (1.25, 3.40) 0.005 
     Mixed 0.81 (0.55, 1.21) 0.312 1.49 (0.85, 2.60) 0.162 
Census region     
     Northeast 1.00 --- 1.00 --- 
     Midwest 2.59 (1.67, 4.01) <0.001 6.63 (2.33, 18.92) <0.001 
     South 3.24 (2.12, 4.94) <0.001 9.83 (3.56, 27.14) <0.001 
     West 2.24 (1.27, 3.97) 0.006 7.77 (2.64, 22.86) <0.001 
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Consistency of health 
insurance 
    
     Current & no gaps 1.00 --- 1.00 --- 
     Intermittent/never insured 1.01 (0.55, 1.84) 0.975 0.96 (0.41, 2.23) 0.921 
11–12 well-child?     
     Yes 1.00 --- 1.00 --- 
     No 1.50 (0.65, 3.45) 0.339 5.11 (2.10, 12.44) <0.001 
# of visits in last 12 months     
     1 1.00 --- 1.00 --- 
     0 1.87 (1.13, 3.11) 0.015 1.62 (0.82, 3.20) 0.167 






Table 13: Multivariate logistic regression between study characteristics and 2+ dose MenACWY 
(Reduced model), NIS-Teen 2018 
Characteristic 
Adjusted OR 
(95% CI) – 1 dose 
only 
p – 1 
dose only 
Adjusted OR 
(95% CI) – no 
doses 
p – no 
doses 
Race/ethnicity     
     Non-Hispanic white 1.00 --- 1.00 --- 
     Non-Hispanic black 0.57 (0.35, 0.94) 0.027 0.31 (0.15, 0.66) 0.002 
     Hispanic 0.74 (0.50, 1.10) 0.131 0.30 (0.16, 0.54) <0.001 
     Other + multiple race 1.03 (0.57, 1.87) 0.919 0.95 (0.47, 1.92) 0.885 
Insurance status     
     Private insurance only 1.00 --- 1.00 --- 
     Any Medicaid 1.17 (0.82, 1.67) 0.399 1.58 (0.93, 2.62) 0.093 
     Other insurance** 1.55 (0.98, 2.44) 0.060 3.44 (1.79, 6.62) <0.001 
     Uninsured 1.74 (0.82, 3.72) 0.150 2.27 (0.82, 6.26) 0.114 
Facility type     
     All private 1.00 --- 1.00 --- 
     Public/hospital/ 
STD/school/teen clinics 
1.17 (0.84, 1.63) 0.350 2.05 (1.28, 3.27) 0.003 
     Mixed 0.90 (0.61, 1.34) 0.612 1.32 (0.77, 2.25) 0.310 
Census region     
     Northeast 1.00 --- 1.00 --- 
     Midwest 2.58 (1.72, 3.88) <0.001 4.34 (1.80, 10.45) 0.001 
     South 3.39 (2.29, 5.03) <0.001 6.58 (2.75, 15.74) <0.001 
     West 2.41 (1.39, 4.15) 0.002 4.84 (1.88, 12.46) 0.001 
11–12 well-child?     
     Yes 1.00 --- 1.00 --- 






Table 14: Multivariate logistic regression between study characteristics and HPV vaccination (Full 




(95% CI) – 
age 17 
completion 











– no doses 
p – no 
doses 
Race/ethnicity       
     Non-Hispanic 
white 
1.00 --- 1.00 --- 1.00 --- 




0.916 0.82 (0.37, 
1.82) 
0.632 0.31 (0.15, 
0.64) 
0.002 
     Hispanic 
0.62 (0.33, 
1.16) 
0.136 0.43 (0.18, 
1.01) 
0.053 0.41 (0.21, 
0.80) 
0.009 




0.309 1.11 (0.50, 
2.50) 
0.796 1.17 (0.56, 
2.42) 
0.678 
Poverty Status       
     Above poverty 
(>$75K) 
1.00 --- 1.00 --- 1.00 --- 




0.697 0.75 (0.40, 
1.38) 
0.351 1.10 (0.65, 
1.85) 
0.727 
     Below poverty 
1.26 (0.59, 
2.70) 
0.556 0.79 (0.28, 
2.27) 
0.666 1.20 (0.56, 
2.59) 
0.640 
Sex       
     Female 1.00 --- 1.00 --- 1.00 --- 
     Male 
1.72 (1.15, 
2.56) 
0.008 2.70 (1.70, 
4.30) 
<0.001 3.34 (2.18, 
5.13) 
<0.001 
Interview Language       
     English 1.00 --- 1.00 --- 1.00 --- 
     Other 
0.61 (0.27, 
1.42) 
0.254 0.62 (0.17, 
2.30) 
0.471 0.32 (0.13, 
0.79) 
0.013 
Insurance status       
     Private insurance 
only 
1.00 --- 1.00 --- 1.00 --- 
     Any Medicaid 
0.54 (0.31, 
0.97) 
0.039 0.69 (0.34, 
1.38) 
0.297 0.54 (0.30, 
0.97) 
0.039 
     Other insurance** 
0.53 (0.25, 
1.13) 
0.097 0.97 (0.39, 
2.40) 
0.963 1.08 (0.50, 
2.34) 
0.839 
     Uninsured 
1.29 (0.40, 
4.14) 
0.668 2.57 (0.59, 
11.18) 





      
     Married 1.00 --- 1.00 --- 1.00 --- 
     Not married*** 
0.99 (0.63, 
1.53) 
0.950 1.16 (0.67, 
2.03) 
0.595 0.77 (0.48, 
1.24) 
0.284 
Maternal education       
     College grad 1.00 --- 1.00 --- 1.00 --- 





0.367 1.26 (0.71, 
2.22) 





     12 years 
0.97 (0.51, 
1.86) 
0.922 1.28 (0.59, 
2.75) 
0.530 1.33 (0.67, 
2.61) 
0.415 
     Less than 12 years 
0.96 (0.48, 
1.94) 
0.918 1.71 (0.65, 
4.49) 





      
     Owned/being 
bought 
1.00 --- 1.00 --- 1.00 --- 
     Rented/other 
1.40 (0.83, 
2.36) 
0.209 1.33 (0.70, 
2.54) 
0.389 1.39 (0.75, 
2.56) 
0.298 
# of children <18       
     1 1.00 --- 1.00 --- 1.00 --- 
     2–3 
1.57 (1.03, 
2.39) 
0.036 0.79 (0.48, 
1.28) 
0.332 1.25 (0.80, 
1.95) 
0.324 
     4+ 
1.30 (0.66, 
2.56) 
0.444 0.98 (0.43, 
2.24) 
0.959 2.96 (1.48, 
5.94) 
0.002 
Facility type       
     All private 1.00 --- 1.00 --- 1.00 --- 





0.232 0.72 (0.40, 
1.31) 
0.281 1.06 (0.63, 
1.78) 
0.826 
     Mixed 
0.91 (0.55, 
1.51) 
0.724 0.63 (0.35, 
1.15) 
0.131 0.76 (0.44, 
1.29) 
0.305 
Census region       
     Northeast 1.00 --- 1.00 --- 1.00 --- 
     Midwest 
0.76 (0.42, 
1.37) 
0.359 1.76 (0.83, 
3.76) 
0.143 1.38 (0.70, 
2.72) 
0.352 
     South 
0.77 (0.45, 
1.33) 
0.345 1.29 (0.64, 
2.60) 
0.471 1.27 (0.68, 
2.40) 
0.454 
     West 
0.79 (0.39, 
1.59) 
0.508 1.62 (0.69, 
3.78) 
0.270 1.08 (0.51, 
2.28) 
0.852 
Consistency of health 
insurance 
      
     Current & no gaps 1.00 --- 1.00 --- 1.00 --- 




0.343 1.41 (0.55, 
3.60) 
0.471 1.07 (0.52, 
2.22) 
0.852 
11–12 well-child?       
     Yes 1.00 --- 1.00 --- 1.00 --- 
     No 
5.84 (1.31, 
26.11) 






# of visits in last 12 
months 
      
     1 1.00 --- 1.00 --- 1.00 --- 
     0 
0.67 (0.32, 
1.41) 
0.294 0.67 (0.29, 
1.54) 
0.342 0.47 (0.23, 
0.99) 
0.046 
     2+ 
1.12 (0.71, 
1.77) 
0.638 1.14 (0.65, 
2.03) 






Table 15: Multivariate logistic regression between study characteristics and HPV vaccination (Reduced 




(95% CI) – 
age 17 
completion 










(95% CI) – 
no doses 
p – no 
doses 
Race/ethnicity       
     Non-Hispanic 
white 
1.00 --- 1.00 --- 1.00 --- 




0.786 0.73 (0.35, 
1.53) 
0.404 0.29 (0.15, 
0.56) 
0.003 
     Hispanic 
0.57 (0.37, 
0.88) 
0.011 0.51 (0.27, 
0.95) 
0.035 0.26 (0.16, 
0.43) 
<0.001 




0.426 0.88 (0.42, 
1.83) 
0.726 0.97 0.50, 
1.90) 
0.931 
Sex       
     Female 1.00 --- 1.00 --- 1.00 --- 
     Male 
2.02 (1.38, 
2.96) 
<0.001 3.36 (2.12, 
5.34) 
<0.001 3.76 (2.52, 
5.60) 
<0.001 
# of children <18       
     1 1.00 --- 1.00 --- 1.00 --- 
     2–3 
1.43 (0.96, 
2.12) 
0.077 0.69 (0.42, 
1.13) 
0.136 1.16 (0.77, 
1.75) 
0.474 
     4+ 
1.22 (1.68, 
2.20) 
0.506 0.82 (0.38, 
1.77) 
0.612 2.14 (1.18, 
3.89) 
0.013 
11–12 well-child?       
     Yes 1.00 --- 1.00 --- 1.00 --- 
     No 
4.86 (1.35, 
17.48) 
0.015 11.69 (3.27, 
41.75) 
<0.001 15.70 
(4.63, 
53.21) 
<0.001 
 
 
